FBN1 and aneurysm: To the best of our knowledge, this is the first study reporting pathogenetic fibrillin 1 mutations in patients with BAV and aortic dilatation/aneurysm in whom MFS and other more severe type 1 fibrillinopathies were clinically excluded according to the updated Ghent criteria [4].